Telomir Pharmaceuticals Valuation Multiples

Telomir Pharmaceuticals Overview

About Telomir Pharmaceuticals

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer’s disease, osteoarthritis, and others.

Founded

2021

HQ

Employees

5

Website

telomirpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: —

EBITDA: ($10M)

EV

$36M

Valuation Multiples

Multiples.vc

Start free trial

Telomir Pharmaceuticals Financials

Telomir Pharmaceuticals reported last fiscal year revenue of — and negative EBITDA of ($10M).

In the same fiscal year, Telomir Pharmaceuticals generated ($10M) in EBITDA losses and had net loss of ($10M).

Telomir Pharmaceuticals P&L

In the most recent fiscal year, Telomir Pharmaceuticals reported revenue of — and EBITDA of ($10M).

Telomir Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Telomir Pharmaceuticals Stock Performance

Telomir Pharmaceuticals has current market cap of $44M, and enterprise value of $36M.

Telomir Pharmaceuticals' stock price is $1.27.

Telomir Pharmaceuticals Valuation Multiples

Telomir Pharmaceuticals trades at (3.5x) EV/EBITDA.

Telomir Pharmaceuticals Financial Valuation Multiples

As of April 11, 2026, Telomir Pharmaceuticals has market cap of $44M and EV of $36M.

Equity research analysts estimate Telomir Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Telomir Pharmaceuticals has a P/E ratio of (4.2x).

Telomir Pharmaceuticals Margins & Growth Rates

Telomir Pharmaceuticals' revenue in the last fiscal year grew by —.

Telomir Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.

Telomir Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Telomir Pharmaceuticals M&A Activity

Telomir Pharmaceuticals acquired XXX companies to date.

Last acquisition by Telomir Pharmaceuticals was on XXXXXXXX, XXXXX. Telomir Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Telomir Pharmaceuticals Investment Activity

Telomir Pharmaceuticals invested in XXX companies to date.

Telomir Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Telomir Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).